Jordan Dimitrakov1, David Guthrie. 1. George O'Brien Center for Urological Diseases Research, Harvard Medical School and Children's Hospital Boston, Boston, Massachusetts, USA.
Abstract
PURPOSE: Interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome, collectively renamed urological chronic pelvic pain syndromes, are a group of medically unexplained physical symptoms. Diagnosis depends on excluding all possible causes of pain and treatment targets symptoms alone. An emerging body of research implicates systemic factors in the pathogenesis of urological chronic pelvic pain syndromes including abnormal sympathetic nervous system and hypothalamic-pituitary-adrenal axis activity. Several new lines of evidence also suggest a genetic component to disease pathogenesis. Despite ongoing efforts, neither effective treatments nor mechanistic understanding of the pathogenesis of urological chronic pelvic pain syndromes exists. MATERIALS AND METHODS: We performed a survey of the available literature on urological chronic pelvic pain syndromes. We reviewed recent research implicating genetic mechanisms in the development of urological chronic pelvic pain syndromes to find a systematic approach of rigorous phenotyping on which to base further investigation of these chronic pain conditions. RESULTS: Three studies revealed identifying genetic risk factors for disease. In addition, increasing lines of evidence of familial clustering and twin studies suggested a genetic basis for disease. CONCLUSIONS: Given the success of genome-wide association studies in quantifying genetic risk in several polygenic diseases, we suggest a similar genome-wide approach to the study of urological chronic pelvic pain syndromes. As genome-wide association studies depend on carefully defined patient populations, we provide an outline for a thorough and multidisciplinary characterization of patient phenotypes. Although urological chronic pelvic pain syndromes continue to mystify clinicians and researchers alike, we believe the powerful new methods of unbiased interrogation of the whole genome based on systematically grouped patients possess enormous potential for progress in treating and understanding this disease.
PURPOSE:Interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome, collectively renamed urological chronic pelvic pain syndromes, are a group of medically unexplained physical symptoms. Diagnosis depends on excluding all possible causes of pain and treatment targets symptoms alone. An emerging body of research implicates systemic factors in the pathogenesis of urological chronic pelvic pain syndromes including abnormal sympathetic nervous system and hypothalamic-pituitary-adrenal axis activity. Several new lines of evidence also suggest a genetic component to disease pathogenesis. Despite ongoing efforts, neither effective treatments nor mechanistic understanding of the pathogenesis of urological chronic pelvic pain syndromes exists. MATERIALS AND METHODS: We performed a survey of the available literature on urological chronic pelvic pain syndromes. We reviewed recent research implicating genetic mechanisms in the development of urological chronic pelvic pain syndromes to find a systematic approach of rigorous phenotyping on which to base further investigation of these chronic pain conditions. RESULTS: Three studies revealed identifying genetic risk factors for disease. In addition, increasing lines of evidence of familial clustering and twin studies suggested a genetic basis for disease. CONCLUSIONS: Given the success of genome-wide association studies in quantifying genetic risk in several polygenic diseases, we suggest a similar genome-wide approach to the study of urological chronic pelvic pain syndromes. As genome-wide association studies depend on carefully defined patient populations, we provide an outline for a thorough and multidisciplinary characterization of patient phenotypes. Although urological chronic pelvic pain syndromes continue to mystify clinicians and researchers alike, we believe the powerful new methods of unbiased interrogation of the whole genome based on systematically grouped patients possess enormous potential for progress in treating and understanding this disease.
Authors: Steven P Hamilton; Abby J Fyer; Martina Durner; Gary A Heiman; Ada Baisre de Leon; Susan E Hodge; James A Knowles; Myrna M Weissman Journal: Proc Natl Acad Sci U S A Date: 2003-02-25 Impact factor: 11.205
Authors: G R Sant; K J Propert; P M Hanno; D Burks; D Culkin; A C Diokno; C Hardy; J R Landis; R Mayer; R Madigan; E M Messing; K Peters; T C Theoharides; J Warren; A J Wein; W Steers; J W Kusek; L M Nyberg Journal: J Urol Date: 2003-09 Impact factor: 7.450
Authors: Myrna M Weissman; Raz Gross; Abby Fyer; Gary A Heiman; Marc J Gameroff; Susan E Hodge; David Kaufman; Steven A Kaplan; Priya J Wickramaratne Journal: Arch Gen Psychiatry Date: 2004-03
Authors: J C Janssen; J A Beck; T A Campbell; A Dickinson; N C Fox; R J Harvey; H Houlden; M N Rossor; J Collinge Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: Lisa Johnson Wright; Carolyn Noonan; Sandra Ahumada; María Angeles Bullones Rodríguez; Dedra Buchwald; Niloofar Afari Journal: Gen Hosp Psychiatry Date: 2010-02-20 Impact factor: 3.238
Authors: James R F Hockley; Rafael González-Cano; Sheridan McMurray; Miguel A Tejada-Giraldez; Cian McGuire; Antonio Torres; Anna L Wilbrey; Vincent Cibert-Goton; Francisco R Nieto; Thomas Pitcher; Charles H Knowles; José Manuel Baeyens; John N Wood; Wendy J Winchester; David C Bulmer; Cruz Miguel Cendán; Gordon McMurray Journal: J Physiol Date: 2017-03-01 Impact factor: 5.182
Authors: Brandon A Mahal; Jeffrey M Cohen; Stephen A Allsop; John B Moore; Salman F Bhai; Gino Inverso; Jordan D Dimitrakoff Journal: Curr Urol Rep Date: 2011-08 Impact factor: 3.092
Authors: Wenbin Yang; Ryan E Yaggie; Mingchen C Jiang; Charles N Rudick; Joseph Done; Charles J Heckman; John M Rosen; Anthony J Schaeffer; David J Klumpp Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-11-08 Impact factor: 3.619